9/#TumorBoardTuesday #OncTwitter #NephTwitter #BonumCE

#ICYMI 🪡#RenalCell #MedTweetorial🧵
w @brian_rini @shilpaonc @katy_beckermann

🦺TKI/IO safety data
🥽Tox to look 4
⛑AE mgmt

---
RT @TumorBoardTues
1/ #OncTwitter #NephTwitter #TumorBoardTuesday
✅#RenalCell #MedTweetorial🧵
w @brian_rini @shilpaonc @katy_beckermann

🦺TKI/IO safety data
🥽Tox to look 4
⛑AE mgmt

🆓#CME @BonumCe🔗http://bit.ly/3VDaK81
Support by edu grants from Eisai…
https://twitter.com/TumorBoardTues/status/1602468719426342913

8/ #TumorBoardTuesday #RenalCell #NephTwitter

🔴#PostTest Q 4️⃣
🗳️ Pt treated w/ combo of cabozantinib + nivolumab develops G3 hypertension. Cabo therapy is held & pt receives anti-hypertensive medication & BP recovers to baseline. At what dose can cabozantinib be restarted?

7/ #TumorBoardTuesday #RenalCell #NephTwitter #MedTwitter #BonumCE
#CME 🔗http://bit.ly/3FamQyu

🔴#PostTest Q3️⃣
🗳️ Pt treated w/ combo of pembrolizumab and lenvatinib for metastatic RCC develops grade 3 diarrhea. How might you diagnose which drug is causing this toxicity?

6/ #TumorBoardTuesday #OncTwitter #RenalCell #NephTwitter #MedTwitter #BonumCE
#CME 🔗http://bit.ly/3FamQyu

🔴#PostTest Q 2️⃣
🗳️ Which of the following is NOT a characteristic of immune-mediated toxicities associated with the use of ICIs?

4/ #TumorBoardTuesday #BonumCE
#RenalCell #NephTwitter #MedTwitter

Let’s revisit efficacy of 🔑Ph3 clin trials:
💎#CLEAR
💎#KEYNOTE426
💎#CheckMate9ER
💎#CheckMate214